How should a 34-year-old man with incidentally discovered hypertension, impaired renal function (serum creatinine ~2 mg/dL), proteinuria ~1.4 g/24 h, and renal biopsy showing thrombotic microangiopathy, but normal hemoglobin and platelet count, be managed?

Management of Renal TMA with Hypertension and Preserved Hematologic Parameters

This 34-year-old man with biopsy-proven renal thrombotic microangiopathy (TMA), hypertension, and proteinuria but normal hemoglobin and platelets requires urgent blood pressure control with gradual reduction targeting 150-160 mmHg systolic initially, followed by stepwise reduction to <130/80 mmHg, combined with ACE inhibitor or ARB therapy for proteinuria management.

Immediate Diagnostic Priorities

The absence of systemic TMA features (normal hemoglobin 13.8 g/dL, normal platelets 278,000/µL) with isolated renal TMA on biopsy indicates either:

• Malignant hypertension-induced renal TMA (most likely given the clinical context) 1
• Early atypical HUS (less likely without hematologic abnormalities)
• Secondary TMA from another cause

Critical Workup Before Treatment

Immediately obtain:

• ADAMTS13 activity level (must be drawn before any plasma therapy) - to exclude TTP 2, 3
• Complement levels (C3, C4, CH50)
• Anti-factor H antibodies
• Stool culture for Shiga toxin-producing E. coli (STEC) if any diarrheal history 3
• Haptoglobin, LDH, peripheral blood smear for schistocytes (may be absent early) 3
• Fundoscopy for hypertensive retinopathy 1

The finding of renal-limited TMA with normal systemic hematologic parameters is well-documented - renal TMA prevalence approaches 95% in malignant hypertension while hematologic TMA occurs in only 73% 4. This discordance is critical for management decisions.

Blood Pressure Management Strategy

Initial Target: Controlled Gradual Reduction

Target systolic BP of 150-160 mmHg initially, then gradual reduction over days to weeks 5. This cautious approach is essential because:

• Precipitous BP reduction can cause acute ischemic injury to already compromised kidneys 5
• The case report of a 55-year-old with similar presentation (malignant hypertension, renal TMA, creatinine 9.27 mg/dL) who lost consciousness after aggressive BP reduction with azilsartan demonstrates this risk 5
• Gradual BP control with low-dose ARB (losartan 12.5-50 mg/day) targeting 150-160 mmHg systolic allowed renal recovery from 9.27 to 4.48 mg/dL over 10 months without dialysis 5

Specific BP Targets by Timeline

First 24-48 hours: Reduce mean arterial pressure (MAP) by 20-25% over several hours 1

Days 2-7: Target systolic BP 150-160 mmHg 5

Week 2 onwards: Gradually reduce to <130/80 mmHg as tolerated 6, 7

Antihypertensive Drug Selection

Start with low-dose ARB or ACE inhibitor:

• Losartan 12.5-25 mg daily OR
• Perindopril 2 mg daily 6

Add calcium channel blocker if needed:

• Amlodipine 5 mg daily 5

Rationale: Despite the elevated creatinine (2.0-2.2 mg/dL), ACE inhibitor/ARB therapy is indicated because:

1. Proteinuria is >1 g/day (1.4 g/24h) - strong indication per KDIGO guidelines 8, 6
2. These agents reduce intraglomerular pressure and proteinuria 6
3. Up to 30% creatinine increase is acceptable and expected 6, 7
4. The malignant hypertension-induced TMA responds to BP control with RAS blockade 5, 9

Proteinuria Management

Target proteinuria <1 g/day 8, 6

With current proteinuria of 1.4 g/24h:

• Uptitrate ACE inhibitor or ARB to maximally tolerated dose as BP allows 8, 6
• Monitor serum creatinine and potassium every 1-2 weeks initially 6
• Accept up to 30% creatinine increase - do not stop RAS blockade unless creatinine continues rising or hyperkalemia develops 6

Monitoring Strategy

Weekly for first month:

• Serum creatinine, potassium
• Blood pressure (home monitoring if possible)
• Urinalysis

Every 2 weeks for months 2-3:

• Complete blood count (watch for development of systemic TMA features)
• Comprehensive metabolic panel
• Spot urine protein-to-creatinine ratio

Monthly thereafter:

• Renal function panel
• Proteinuria assessment

When to Consider Complement Blockade

Eculizumab is NOT indicated initially because:

• Normal platelets and hemoglobin argue against active complement-mediated TMA 3
• Malignant hypertension-induced TMA typically responds to BP control alone 9, 10
• One case series showed no benefit from eculizumab in hypertension-induced TMA 11

Consider eculizumab only if:

• Platelets drop below 150,000/µL or decline >25% 3
• Hemoglobin falls with evidence of hemolysis (elevated LDH, low haptoglobin, schistocytes)
• Renal function deteriorates despite adequate BP control
• Genetic testing reveals complement mutation

Plasma Exchange: Not Indicated

Do NOT initiate plasma exchange unless:

• ADAMTS13 activity returns <10% (TTP diagnosis) 2
• Rapid clinical deterioration with systemic TMA features develops

The evidence shows malignant hypertension-induced TMA responds to BP control without plasma exchange 9, 10. Unnecessary plasma exchange carries significant risks and costs.

Common Pitfalls to Avoid

1. Overly aggressive BP reduction - causes syncope and worsens renal ischemia 5
2. Withholding ACE inhibitor/ARB due to elevated creatinine - proteinuria >1 g/day is a strong indication despite CKD stage 3 6
3. Assuming systemic TMA requires plasma exchange - renal-limited TMA with normal hematologic parameters responds to BP control 4
4. Stopping ACE inhibitor/ARB for 30% creatinine rise - this is expected and acceptable 6
5. Empiric eculizumab without excluding secondary causes - expensive and unnecessary if hypertension-induced 10

Expected Outcomes

With appropriate gradual BP control and RAS blockade:

• Renal function stabilization or improvement over 3-12 months 5, 9
• Proteinuria reduction with uptitrated ACE inhibitor/ARB 6
• Avoidance of dialysis in most cases if BP controlled early 5, 9

The prognosis is generally favorable if hypertension is the primary driver, as demonstrated by multiple case reports showing renal recovery with BP control alone 5, 9, 12.